Transverse Myelitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to give your consent to take part in the study
- You are a woman who is able to become pregnant and have been diagnosed with, or are suspected to have, a condition called NMOSD (a rare disease affecting the nerves and spinal cord)
- You were exposed to a medication called UPLIZNA (inebilizumab) either during your pregnancy or within 6 months before becoming pregnant
Who may not be able to join:
- There may be additional requirements or restrictions set by the study team that are not listed here (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MD, Amgen
Phone: 866-572-6436
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of newborns with Major Congenital Malformations (MCMs); Number of newborns with Preterm birth; Number of newborns with low birth weight; Number of stillbirths
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.